Ad hoc announcement pursuant to Art. 53 LR

Here is the original post:
Novartis plans to petition the U.S. Court of Appeals for the Federal Circuit for further review to uphold validity of the Gilenya® (fingolimod)...

- Vote to approve share consolidation adjourned to July 6, 2022

Read more from the original source:
Aeterna Zentaris Announces Results of Annual Meeting of Shareholders

Webcast presentation tomorrow, Wednesday, 22 June 2022, at 14.00 CET / 8 AM ET, www.glpg.com

Read more here:
Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies

-- Phase 2b Study in MAB Pulmonary Infections Ongoing and Enrolling as Planned

Read the original:
Paratek Pharmaceuticals’ NUZYRA® Receives FDA Fast Track Designation for the Treatment of Pulmonary Nontuberculous Mycobacterial (NTM) Disease...

WESTMINSTER, Colo., June 21, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that Jacob Ma-Weaver has joined its Board of Directors.

Link:
Jacob Ma-Weaver Joins ARCA biopharma Board of Directors

TORONTO, June 21, 2022 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. ("Dialco"), today announced the results of its Annual and Special Meeting of shareholders (the "Shareholders") held on June 20, 2022 (the "Meeting"). The Company is pleased to announce that all resolutions put forward in the Management Information Circular dated May 6, 2022 (the "Circular") to its Shareholders were approved.

See the original post:
Spectral Medical Inc. Announces Results of Annual and Special Meeting of Shareholders

PHILADELPHIA, June 21, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, will participate in a fireside chat at the LifeSci Partners 2nd Annual Genetic Medicines Symposium on June 28, 2022, at 9:30 AM ET.

More here:
Century Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium

JERSEY, Channel Islands, June 21, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced that it is rescheduling the release of its financial results for the fourth quarter and full year 2022 ended March 31, 2022. The Company will release these financial results and host a conference call before market open on Friday, June 24, 2022.

Read more:
Quotient Limited Reschedules Fourth Quarter and Full Year 2022 Financial Results Announcement to Friday, June 24th and Provides a Preview of...

– The INSPIRE trial achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments –

Read more:
Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome

CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today held its Annual Meeting of Shareholders (the “Meeting”) in Calgary, Alberta.

Here is the original post:
Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders